Answer
Regadenoson is unlikely to alter the pharmacokinetics of medicines metabolised by CYP3A4, as it does not inhibit CYP3A4 substrate metabolism in human liver microsomes.
Sources for this answer
- Rapiscan 400 microgram solution for injectionGE Healthcare Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 3Document updated
Sources checked